FDA Approves Osimertinib/Chemo in EGFR-Mutated NSCLC

News
Article

Data from the phase 3 FLAURA 2 trial support the FDA approval of osimertinib plus chemotherapy for treating patients with EGFR-mutated non–small cell lung cancer.

Supporting data for the FDA approval of osimertinib in EGFR-mutated non–small cell lung cancer came from the phase 3 FLAURA 2 trial (NCT04035486).

Supporting data for the FDA approval of osimertinib in EGFR-mutated non–small cell lung cancer came from the phase 3 FLAURA 2 trial (NCT04035486).

The FDA has granted approval to osimertinib (Tagrisso) in combination with platinum-based chemotherapy as a treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations, according to a press release from the agency.1

The regulatory agency approved osimertinib at a recommended dose of 80 mg orally twice a day with or without food until acceptable toxicity or progressive disease.

Supporting data for the approval of osimertinib in this indication came from the phase 3 FLAURA 2 trial (NCT04035486). Data highlighted a median progression-free survival (PFS) of 25.5 months (95% CI, 24.7-not estimable [NE) with osimertinib plus chemotherapy compared with 16.7 months (95% CI, 14.1-21.3) in those who received osimertinib monotherapy (HR, 0.62; 95% CI, 0.49-0.79; P <.0001).

Currently, overall survival data are still immature, but 45% of prespecified deaths were reported, and there was not a detriment observed.

In the open-label FLAURA 2 trial, 557 patients with EGFR-mutated advanced or metastatic NSCLC were randomly assigned 1:1 to receive osimertinib alone or in combination with platinum-containing chemotherapy.

The trial’s primary efficacy end point was PFS per investigator assessment. OS was a key secondary end point.

The most common adverse effects observed in the osimertinib/chemotherapy arm included leukopenia, thrombocytopenia, neutropenia, lymphopenia, and rash.

The FDA previously granted priority review to a supplemental biologics license application for osimertinib as a treatment for those with advanced or metastatic NSCLC harboring EGFR mutations in October 2023.2

References

  1. FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer. News release. FDA. February 16, 2024. Accessed February 16, 2024. https://bit.ly/49AeXjy
  2. Tagrisso plus chemotherapy granted priority review in the US for patients with EGFR-mutated advanced lung cancer. News release. AstraZeneca. October 16, 2023. Accessed February 16, 2024. https://bit.ly/3ZUDUm9
Recent Videos
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Related Content
City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC

City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC

ONCOLOGY Staff
October 24th 2024
Article

Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.

FDA Places Partial Clinical Hold on Phase 3 Gotistobart NSCLC Trial

Russ Conroy
October 21st 2024
Article

The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Support for the approval comes from phase 3 LUNAR study findings indicating TTFields significantly prolonged OS compared with standard of care alone.

FDA Approves TTFields for Previously Treated Metastatic NSCLC

Roman Fabbricatore;Russ Conroy
October 15th 2024
Article

Support for the approval comes from phase 3 LUNAR study findings indicating TTFields significantly prolonged OS compared with standard of care alone.

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.

Stereotactic Radiosurgery/TKIs Improves CNS Outcomes in EGFR/ALK+ NSCLC

Russ Conroy
October 11th 2024
Article

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.